Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma

OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. PATIENTS AND METHODS: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg i...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jianping, Liu, Xiaoyan, Yang, Sheng, Zhang, Xiangru, Shi, Yuankai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876100/
https://www.ncbi.nlm.nih.gov/pubmed/27274284
http://dx.doi.org/10.2147/OTT.S102472
_version_ 1782433187001008128
author Xu, Jianping
Liu, Xiaoyan
Yang, Sheng
Zhang, Xiangru
Shi, Yuankai
author_facet Xu, Jianping
Liu, Xiaoyan
Yang, Sheng
Zhang, Xiangru
Shi, Yuankai
author_sort Xu, Jianping
collection PubMed
description OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. PATIENTS AND METHODS: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded. RESULTS: For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment. CONCLUSION: Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma.
format Online
Article
Text
id pubmed-4876100
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48761002016-06-07 Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma Xu, Jianping Liu, Xiaoyan Yang, Sheng Zhang, Xiangru Shi, Yuankai Onco Targets Ther Original Research OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of icotinib in patients with brain metastases (BMs) from lung adenocarcinoma. PATIENTS AND METHODS: Clinical data of 28 cases with BMs from lung adenocarcinoma were retrospectively analyzed. All the patients took 125 mg icotinib orally three times a day. Progression of disease, intolerable adverse reactions, and number of deaths were recorded. RESULTS: For all the patients, the remission rate of icotinib was 67.8% and the disease control rate was 96.4%. The median overall survival time of patients was 21.2 months, and the median progression-free survival time of patients was 10.9 months. Only mild adverse events of grade 1/2 were observed during the treatment. CONCLUSION: Icotinib was an effective and safe strategy to treat patients with BMs from lung adenocarcinoma. Dove Medical Press 2016-05-17 /pmc/articles/PMC4876100/ /pubmed/27274284 http://dx.doi.org/10.2147/OTT.S102472 Text en © 2016 Xu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Xu, Jianping
Liu, Xiaoyan
Yang, Sheng
Zhang, Xiangru
Shi, Yuankai
Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title_full Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title_fullStr Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title_full_unstemmed Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title_short Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
title_sort efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876100/
https://www.ncbi.nlm.nih.gov/pubmed/27274284
http://dx.doi.org/10.2147/OTT.S102472
work_keys_str_mv AT xujianping efficacyandsafetyoficotinibinpatientswithbrainmetastasesfromlungadenocarcinoma
AT liuxiaoyan efficacyandsafetyoficotinibinpatientswithbrainmetastasesfromlungadenocarcinoma
AT yangsheng efficacyandsafetyoficotinibinpatientswithbrainmetastasesfromlungadenocarcinoma
AT zhangxiangru efficacyandsafetyoficotinibinpatientswithbrainmetastasesfromlungadenocarcinoma
AT shiyuankai efficacyandsafetyoficotinibinpatientswithbrainmetastasesfromlungadenocarcinoma

Ejemplares similares